RLLVF (Relevium Technologies) 3-Year ROIIC % : 0.00% (As of Jun. 2021)


What is Relevium Technologies 3-Year ROIIC %?

Relevium Technologies RLLVF -99.98% 3-Year ROIIC % is 0.00 as of Jun. 2021.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Relevium Technologies's 3-Year ROIIC % for the quarter that ended in Jun. 2021 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Relevium Technologies's 3-Year ROIIC % or its related term are showing as below:

RLLVF's 3-Year ROIIC % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 3.28
* Ranked among companies with meaningful 3-Year ROIIC % only.

Relevium Technologies  (OTCPK:RLLVF) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Relevium Technologies 3-Year ROIIC % Related Terms


Relevium Technologies 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Relevium Technologies's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relevium Technologies 3-Year ROIIC % Chart

Relevium Technologies Annual Data
Trend Dec12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Relevium Technologies Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RLLVF vs HEWA, SSY: 3-Year ROIIC % Comparison

For the Pharmaceutical Retailers subindustry, Relevium Technologies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relevium Technologies 3-Year ROIIC % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Relevium Technologies's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Relevium Technologies's 3-Year ROIIC % falls into.



Relevium Technologies 3-Year ROIIC % Calculation

Relevium Technologies's 3-Year ROIIC % for the quarter that ended in Jun. 2021 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -1.207 (Jun. 2021) - -1.634 (Jun. 2018) )/( 3.996 (Jun. 2021) - 6.559 (Jun. 2018) )
=0.427/-2.563
=-16.66%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of 0.00 mean?
Relevium Technologies (RLLVF) has a 3-Year ROIIC % of 0.00 as of Jun. 2021. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Relevium Technologies and its competitors.
Is Relevium Technologies' 3-Year ROIIC % too high?
Relevium Technologies' current 3-Year ROIIC % is 0.00.
How does Relevium Technologies' 3-Year ROIIC % compare to HEWA and SSY?
Relevium Technologies' 3-Year ROIIC % of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median 3-Year ROIIC % is 3.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.28, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Relevium Technologies and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relevium Technologies's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relevium Technologies stock overvalued right now?
Relevium Technologies (RLLVF) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Relevium Technologies (RLLVF), the current 3-Year ROIIC % is 0.00 as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relevium Technologies Business Description

Address 1000 Sherbrooke Street West, Suite 2700, Montreal, QC, CAN, H3A 3G4
Relevium Technologies Inc is a Canada based company operates in the health and wellness industry with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition, and operations of brands and businesses in the health and wellness markets including medical cannabis. Its operating segment includes Consumer Packaged Goods (CPG); Pediatric Biopharma and Corporate. The company generates maximum revenue from Consumer Packaged Goods segment.